SCHEMBL5465704

SCHEMBL5465704

NC(=O)c1c(NC(=O)Nc2ccc(OCc3ccccc3)cc2)sc2c1CCOC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
EPHB4 P54760 1/20 0.51
KCNH2 Q12809 5/20 0.50
CFTR P13569 1/20 0.50
TNIK Q9UKE5 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CXCR2 P25025 2/20 0.47
NOX1 Q9Y5S8 2/20 0.46
FLT3 P36888 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
LTA4H P09960 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
RAB7A P51149 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457809 0.88 MEN1 (0.55) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5458514 0.87 FLT3 (0.61) NPC1RAB9AMEN1KMT2ATNIK
SCHEMBL5457892 0.87 CFTR (0.56) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5455947 0.86 MEN1 (0.65) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5453175 0.85 CFTR (0.54) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5460547 0.85 MEN1 (0.58) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5467129 0.84 TNIK (0.50) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5453424 0.84 CFTR (0.59) NPC1RAB9AMEN1KMT2AEPHB4
SCHEMBL5447192 0.83 CFTR (0.52) NPC1RAB9AMEN1KMT2AEPHB4
Bromide SCHEMBL5456268 0.82 MEN1 (0.51) NPC1RAB9AMEN1KMT2AEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 NPC1 2627/4885RAB9A 948/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.